Selected Publication:
SHR
Neuro
Cancer
Cardio
Lipid
Metab
Microb
Mossbock, G; Weger, M; Meinitzer, A; Semmelrock, J; Schmut, O; Faschinger, C; Zimmermann, C; Renner, W; Stanger, O.
Asymmetric dimethylarginine and homocysteine in primary open angle glaucoma
SPEKTRUM AUGENHEILKD. 2009; 23(5): 333-336.
Doi: 10.1007/s00717-009-0351-8
Web of Science
FullText
FullText_MUG
- Leading authors Med Uni Graz
-
Mossböck Georg
- Co-authors Med Uni Graz
-
Faschinger Christoph
-
Meinitzer Andreas
-
Renner Wilfried
-
Schmut Otto
-
Semmelrock Hans-Jürgen
-
Weger Martin
-
Zimmermann-Roth Christina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Endothelial dysfunction has been implicated in the pathogenesis of primary open angle glaucoma (POAG). Nitric oxide (NO), synthesized from L-arginine by nitric oxide synthase (NOS), is the most important endothelial derived vasodilative substance. Asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor, leads to decreased NO bio-availability, while homocysteine has been associated with increased ADMA plasma levels. Furthermore, due to its neurotoxic and gliotoxic properties, homocysteine has been suggested to be a risk factor for POAG. METHODS: The present case-control study comprised 44 patients with POAG and 44 control subjects, matched for age and gender. Plasma levels of ADMA and homocysteine were determined using high-performance liquid chromatography. RESULTS: No significant difference in either mean ADMA or homocysteine plasma levels was found between patients and control subjects. Mean plasma level of ADMA was 0.75 +/- 0.09 A mu mol/l in patients and 0.72 +/- 0.09 A mu mol/l in control subjects (p = 0.10), while mean plasma level of homocysteine was 14.6 +/- 5.1 A mu mol/l and 12.9 +/- 3.7 A mu mol/l (p = 0.21), respectively. CONCLUSIONS: The present study suggests that plasma levels of ADMA and homocysteine are not associated with increased risk for POAG.
- Find related publications in this database (Keywords)
-
ADMA
-
homocysteine
-
NO
-
primary open-angle glaucoma